Topics

No keywords indexed for this article. Browse by subject →

References
35
[1]
Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna et al.

New England Journal of Medicine 10.1056/nejmoa2032183
[5]
Collins L Costello RA. Glucagon-like peptide-1 receptor agonists. 2019. https://www.ncbi.nlm.nih.gov/books/NBK551568/
[7]
Nordisk N. Novo Nordisk annual report 2021. Novo Nordisk Webpage; 2022. Bagsværd, Denmark
[10]
Madsen LR. Svær overvægt: ikke-kirurgisk behandling. Endocrinology.dk. 2023. https://endocrinology.dk/nbv/andre-endokrinologiske-sygdomme/non-kirurgisk-behandling-af-svaer-overvaegt/
[16]
Guyatt G. User’s guides to the medical literature. JAMA Evidence; 2008. American Journal of Evaluation
[32]
Damsgaard D. Patienterne er vilde efter vægttabsmiddel. 2022. https://ugeskriftet.dk/nyhed/patienterne-er-vilde-efter-vaegttabsmiddel
Metrics
9
Citations
35
References
Details
Published
Mar 12, 2025
Vol/Issue
43(2)
Pages
370-379
License
View
Cite This Article
Christoffer Kraul Ibsen, Marius Brostrøm Kousgaard, Sofie Olsen, et al. (2025). Patients’ experiences with GLP1-RAs – a systematic review. Scandinavian Journal of Primary Health Care, 43(2), 370-379. https://doi.org/10.1080/02813432.2025.2477141